Log in to your Inderes Free account to see all free content on this page.
Pharma Equity Group
0.199 DKK -0.25%HC Andersen Capital receives payment from Pharma Equity Group for a DigitalIR/Corporate Visibility agreement. See disclaimer.
11 investors are following this company
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
PEG
Daily low / high price
0.195 / 0.2
DKK
Market cap
203.57M DKK
Turnover
89.66K DKK
Volume
453K
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Claus Thestrup
CEO, Sweden
Financial calendar
Interim report
16.05.2024
Extraordinary general meeting
03.06.2024
Interim report
16.08.2024
Interim report
15.11.2024
ShowingAll content types
Notice convening the extraordinary general meeting of Pharma Equity Group A/S
Life Science seminar 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio